Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2026-04-02 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
2025年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2025 年年度报告全文" which translates to "2025 Annual Report Full Text" for Northeast Pharmaceutical Group Co., Ltd. It contains detailed sections typical of an annual report, including management discussion and analysis, company governance, financial statements, audit report, and notes on accounting policies. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of audited financial statements and comprehensive company information confirms it is the official yearly report covering company activity and full financial performance. FY 2025
2026-04-02 Chinese
公司章程
Governance Information Classification · 95% confidence The document is a detailed corporate charter or articles of association for a company named Northeast Pharmaceutical Group Co., Ltd. It includes comprehensive sections on company organization, shareholder rights, board of directors, management, financial accounting, audit, shareholder meetings, voting procedures, and other governance matters. The content is legal and regulatory in nature, focusing on the internal rules, structure, and governance practices of the company rather than financial results, audit opinions, or announcements. It does not contain financial statements or earnings data, nor is it a brief announcement or presentation. Therefore, it fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2026-03-04 Chinese
北京德恒律师事务所关于东北制药集团股份有限公司2026年第一次临时股东会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality of the procedures and validity of resolutions passed at the 2026 first extraordinary general meeting (临时股东会) of Northeast Pharmaceutical Group Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or financial performance data, nor is it a report of financial results. It is not a simple announcement but a formal legal opinion on the meeting's procedural compliance and voting results. This type of document aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and confirms their legality and validity.
2026-03-04 Chinese
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2026 first extraordinary general meeting of shareholders of Northeast Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on a proposal to amend the company bylaws, and includes a legal opinion from a law firm confirming the legality of the meeting and resolutions. The document does not contain financial statements or detailed financial analysis, but rather the official voting results and meeting details. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA). The document length is short (1782 characters), and it is not a report publication announcement or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2026-03-04 Chinese
关于开展金融衍生品交易业务的可行性分析报告
Management Reports Classification · 95% confidence The document is titled as a "Feasibility Analysis Report on Conducting Financial Derivatives Trading Business" by Dongbei Pharmaceutical Group Co., Ltd. It discusses the company's plan to engage in financial derivatives trading to hedge currency and interest rate risks related to its business operations. The document outlines the background, necessity, types of derivatives to be used, risk analysis, and risk control measures. It is a detailed internal analysis report rather than a regulatory filing, announcement, or financial statement. The document length is 2216 characters, which is relatively short but contains substantive content about the company's financial risk management strategy. It does not contain financial statements or quarterly/yearly financial results, so it is not an Annual Report (10-K) or Interim Report (IR). It is not an announcement of a report publication, nor a certification or voting result. It is also not a call transcript, capital update, or legal proceeding. The content fits best with a Management Report (MDA) as it explains management's analysis and approach to financial risk management through derivatives.
2026-02-13 Chinese
关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for the convening of the 2026 first extraordinary general meeting (临时股东会) of Northeast Pharmaceutical Group Co., Ltd. It details the meeting time, location, voting procedures, agenda items, and proxy voting instructions. It does not contain financial statements, audit results, or management discussion and analysis. The document is primarily an announcement about the meeting and voting process rather than a report or results announcement. The length is 3320 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to solicit votes for the meeting proposals.
2026-02-13 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.